BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Special Report

Japan Looks Beyond Its Borders to Build the Next Generation of Biotech Innovation

Japan’s biotechnology sector is entering a new phase in which scientific strength alone may no longer determine success. As drug development becomes ...

July 20, 2026 | News

Malaysia Positions Biotechnology as a Bridge Between Asian Innovation and Global Markets

As Asia’s biotechnology sector moves from scientific capability towards commercial scale, Malaysia is positioning itself as an increasingly i...

July 20, 2026 | News

India’s Life Sciences Proposition Expands from Global Scale to Strategic Innovation

India’s position in the global life sciences economy has long been anchored in scale — from active pharmaceutical ingredients (APIs) and generi...

July 20, 2026 | News

The Netherlands Positions Itself as Europe’s Gateway for Life Sciences Innovation

For biotechnology companies looking towards Europe, the opportunity is considerable—but so is the complexity. Accessing one of the world’s larg...

July 20, 2026 | News

Hong Kong Makes Its Case as Asia’s Biotech Super-Connector: Capital, Regulation and Scale Converge

Hong Kong is seeking to redefine its place in the global life sciences economy. No longer content to be viewed primarily as a financial gateway int...

July 20, 2026 | News

Australia and Taiwan Build a Faster Clinical Bridge for Global Biotech Development

As biotechnology companies face mounting pressure to move promising science into human studies faster, the relationship between Australia and Taiwa...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

The Technology Is Ready. Are APAC’s Regulators?

In a process-development suite in Singapore, or Hyderabad, or Songdo, a perfusion bioreactor can now run for weeks, its output feeding straight into a conn...

July 15, 2026 | Regulatory

Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme

-- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline o...

July 15, 2026 | News

The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.

A control room that thinks it knows what happens next Walk the mezzanine above a modern biologics suite in Singapore, Songdo or Hyderabad and the change i...

July 13, 2026 | Analysis

APAC's Peptide-Capacity Gamble

For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first &mdash...

July 09, 2026 | Analysis

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Stay Connected